Esta compañía no ha anunciado ningún dividendo en el próximo trimestre, ni ha pagado dividendos en el último año.
Sobre 89bio, Inc.
Rohan Palekar, MBA
89bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded in January 2018 and is headquartered in San Francisco, CA.